Sales of Elevidys are quickly gaining ground on Sarepta's exon-skipping trio, which need to be dosed chronically. In the ...

Sarepta has stopped developing SRP-5051, its exon 51-skipping therapy for Duchenne MD, due to long-term safety concerns and ...

Clinical development and trial testing of vesleteplirsen (SRP-5051) for Duchenne muscular dystrophy (DMD) was stopped, with ...

The FDA has approved FoundationOne Liquid CDx as a companion diagnostic for patients with metastatic non–small cell lung ...

Elevidys sales have increased since the FDA made a controversial choice to expand the therapy's use. Meanwhile, Sarepta is ...

FoundationOne Liquid CDx is now FDA-approved to identify mNSCLC patients with MET exon 14 skipping alterations for tepotinib ...

In operable non-small cell lung cancer (NSCLC), molecular residual disease (MRD) detection via circulating tumor DNA (ctDNA) has emerged as a ...

The study included 49 NSCLC patients who underwent surgery and had next-generation sequencing (NGS)-confirmed oncogenic fusions, MET exon 14 skipping, or de novo MET amplification. After excluding ...

The US biopharma will discontinue development of the Exondys 51 (eteplirsen) follow up treatment to focus on other treatment candidates.

Sarepta Therapeutics Inc (SRPT) reports a robust 39% revenue growth, achieving profitability while navigating strategic ...